Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

A Multicenter, Investigator- and Subject-Blind, Randomized, Placebo-Controlled, Parallel-Group, Repeat-Dose Study to Evaluate the Effect of CDP7657 in Subjects With Active Systemic Lupus Erythematosus

To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.

Inclusion Criteria:

• Patients with Systemic Lupus Erythematosus (SLE)

Exclusion Criteria:

• Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE)
• History of chronic, recurrent, or recent severe infection
• Significant hematologic abnormalities
• History of cancer, heart failure, renal disease, liver disease or other serious illness